Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib

Non-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and druggable lesion is observed (EGFR, ALK, ROS). KRAS is one of the most frequently mutated genes in NSCLC and patients harboring these mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiola, Elisa, Frapolli, Roberta, Tomanelli, Michele, Valerio, Rossana, Iezzi, Alice, Garassino, Marina C., Broggini, Massimo, Marabese, Mirko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772438/
https://www.ncbi.nlm.nih.gov/pubmed/29343688
http://dx.doi.org/10.1038/s41598-017-18900-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772438/
https://www.ncbi.nlm.nih.gov/pubmed/29343688
http://dx.doi.org/10.1038/s41598-017-18900-y

Ejemplares similares